Switch theme
Sign up to access all valuation multiples
Salus is a Slovenia-based company engaged in the wholesale and distribution of medical products. It offers medicines, medical devices, medical supplies, dietary supplements, cosmetics to hospitals, pharmacies, and other customers.
1969
413
Last FY Revenue $766M
Last FY EBITDA $30.2M
$420M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Salus achieved revenue of $766M and an EBITDA of $30.2M.
Salus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Salus valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $766M | XXX | XXX | XXX |
| Gross Profit | XXX | $86.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 11% | XXX | XXX | XXX |
| EBITDA | XXX | $30.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 4% | XXX | XXX | XXX |
| EBIT | XXX | $19.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $15.2M | XXX | XXX | XXX |
| Net Margin | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, Salus's stock price is EUR 42 (or $50).
Salus has current market cap of EUR 345M (or $408M), and EV of EUR 356M (or $420M).
See Salus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $420M | $408M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, Salus has market cap of $408M and EV of $420M.
Salus's trades at 0.5x EV/Revenue multiple, and 13.9x EV/EBITDA.
Equity research analysts estimate Salus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Salus's P/E ratio is not available.
See valuation multiples for Salus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $408M | XXX | $408M | XXX | XXX | XXX |
| EV (current) | $420M | XXX | $420M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 21.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 26.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 44.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSalus's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.2M for the same period.
Salus's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Salus's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Salus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Salus acquired XXX companies to date.
Last acquisition by Salus was XXXXXXXX, XXXXX XXXXX XXXXXX . Salus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Salus founded? | Salus was founded in 1969. |
| Where is Salus headquartered? | Salus is headquartered in Slovenia. |
| How many employees does Salus have? | As of today, Salus has 413 employees. |
| Is Salus publicy listed? | Yes, Salus is a public company listed on LJU. |
| What is the stock symbol of Salus? | Salus trades under SALR ticker. |
| When did Salus go public? | Salus went public in 1999. |
| Who are competitors of Salus? | Similar companies to Salus include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Salus? | Salus's current market cap is $408M |
| Is Salus profitable? | Yes, Salus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
